Pixaban is an anticoagulant for the treatment of venous thromboembolic events.
it is taken by mouth.
it is a direct factor xa inhibitor.
apixaban was approved in the u.s.
in 2014 for treatment and secondary prophylaxis of deep vein thrombosis (dvt) and pulmonary embolism (pe).

apixaban is indicated for the following:
*to lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation.
*deep vein thrombosis (dvt) prophylaxis.
dvt s may lead to pulmonary embolism (pe) in knee or hip replacement surgery patients.
*treatment of both dvt and pe.
*to reduce the risk of recurring dvt and pe after initial therapy.